What do oncologists need to know about biosimilar products?
| Autor: | Kevin Mok, Stephen L. Chan, Linda K.S. Leung, Calvin Liu |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
0301 basic medicine
Background information medicine.medical_specialty Antineoplastic Agents Review lcsh:RC254-282 03 medical and health sciences Biologic Products 0302 clinical medicine Need to know Trastuzumab Neoplasms medicine Humans Intensive care medicine Biologic products Biosimilar Pharmaceuticals business.industry Biosimilar lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Review article 030104 developmental biology Oncology 030220 oncology & carcinogenesis Practice Guidelines as Topic Biosimilar products business Healthcare system medicine.drug Regulation |
| Zdroj: | Chinese Journal of Cancer Chinese Journal of Cancer, Vol 35, Iss 1, Pp 1-11 (2016) |
| ISSN: | 1944-446X |
| Popis: | Many biologic products have improved the outcomes of cancer patients, but the costs can substantially burden healthcare systems. Biosimilar products can potentially reduce drug costs and increase patient access to beneficial treatments. Approval of a biosimilar product relies on the demonstration of “comparability” or “no clinically meaningful differences” as compared to its reference biologic product. Biosimilar products for erythropoietin, granulocyte colony-stimulating factor, trastuzumab, and rituximab are already available, and the regulatory processes in various countries are constantly evolving. It is important that oncologists be familiar with the potential issues surrounding the clinical use of biosimilar products. In this review article, we provide background information about biosimilar products and their regulatory approval processes, followed by a discussion of individual biosimilar drugs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink